TITLE

Comparison of 2 Regimens that Include Interferon-α -2a plus Ribavirin for Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus--Coinfected Patients

AUTHOR(S)
Neau, Didier; Trimoulet, Pascale; Winnock, Maria; Rullier, Anne; Le Bail, Brigitte; Lacoste, Denis; Ragnaud, Jean-Marie; Bioulac-Sage, Paulette; lafon, Marie-Edith; Chêne, Geneviève; Dupon, Michel
PUB. DATE
June 2003
SOURCE
Clinical Infectious Diseases;6/15/2003, Vol. 36 Issue 12, p1564
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
An open-label, randomized trial was conducted to compare the efficacy and safety of 2 regimens of interferon-α-2a (IFN-a-2a) plus ribavirin for management of chronic hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-coinfected patients. Sixty-eight patients were randomized to receive IFN-α-2a at a dosage of either (1) 6 MU given 3 times per week for 24 weeks, followed by 3 MU 3 times per week for an additional 24 weeks (group A; 31 patients); or (2) 9 MU per day for 2 weeks, followed by 3 MU per day for 22 weeks, followed by 3 MU 3 times per week for 24 weeks (group B; 37 patients). Ribavirin was added at week 16 of therapy if HCV RNA remained detectable at week 12. Sustained virological response was achieved in 10 patients (15%; 6 in group A and 4 in group B). HCV genotypes 2 or 3 and a decrease in the HCV load of ≥3 log[SUB10] copies/mL between inclusion and week 4 were associated with virological response. In conclusion,) the combination of conventional IFN-α-2a and ribavirin has poor virological efficacy in HCV-HIV-coinfected patients.
ACCESSION #
10024028

 

Related Articles

  • Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. Dieterich, Douglas T. // Journal of Infectious Diseases;5/16/2002 Supplement 2, Vol. 185, pS128 

    Because of shared modes of transmission, co-infection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) is common. Co-infection with HIV increases HCV virus load, liver-related mortality, and the risk of sexual and perinatal transmission of HCV, and it may accelerate HCV...

  • Addition of Nitazoxanide to PEG-IFN and Ribavirin to Improve HCV Treatment Response in HIV-1 and HCV Genotype 1 Coinfected Persons Naïve to HCV Therapy: Results of the ACTG A5269 Trial. Amorosa, Valerianna K.; Luetkemeyer, Anne; Kang, Minhee; Johnson, Victoria A.; Umbleja, Triin; Haas, David W.; Yesmin, Suria; Bardin, Matthew C.; Chung, Ray T.; Alston-Smith, Beverly; Tebas, Pablo; Peters, Marion G. // HIV Clinical Trials (Thomas Land Publishers Incorporated);Nov/Dec2013, Vol. 14 Issue 6, p274 

    Background: We hypothesized that nitazoxanide (NTZ) added to pegylated interferon alfa-2a (PEG-IFN) and weight-based ribavirin (WBR) would improve hepatitis C virus (HCV) virologic responses in HCV treatment-naïve HIV-1/HCV genotype 1 coinfected persons. Methods: Prospective, single-arm study...

  • A 24-Week Treatment Strategy With Pegylated Interferon/Ribavirin in HIV/Hepatitis C Virus Genotype 3–Coinfected Patients Who Achieved a Rapid Virologic Response Results in a High Sustained Virologic Response Rate. Rivero-Juarez, Antonio; López-Cortés, Luis F.; Camacho, Angela; Mira, Jose A.; Téllez, Francisco; Marquez, Manuel; Merino, Dolores; Pineda, Juan A.; Rivero, Antonio // Clinical Infectious Diseases;Jan2014, Vol. 58 Issue 1, p130 

    We designed a study to evaluate the efficacy of a 24-week treatment strategy in HIV/hepatitis C virus (HCV) genotype 3–coinfected patients achieving rapid virologic response for a first HCV treatment with pegylated interferon plus ribavirin (peg-IFN/RBV). Our results suggest that a...

  • Genetic Variability of Hepatitis C Virus (HCV) 5’ Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin. Bukowska-Ośko, Iwona; Pawełczyk, Agnieszka; Perlejewski, Karol; Kubisa, Natalia; Caraballo Cortés, Kamila; Rosińska, Magdalena; Płoski, Rafał; Fic, Maria; Kaźmierczak, Justyna; Popiel, Marta; Ząbek, Piotr; Horban, Andrzej; Radkowski, Marek; Laskus, Tomasz // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Association between hepatitis C virus (HCV) quasispecies and treatment outcome among patients with chronic hepatitis C has been the subject of many studies. However, these studies focused mainly on viral variable regions (E1 and E2) and usually did not include human immunodeficiency virus...

  • Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. Medrano, Jose; Neukam, Karin; Rallón, Norma; Rivero, Antonio; Resino, Salvador; Naggie, Susanna; Caruz, Antonio; Calvino, Aida; Macías, Juan; Benito, Jose Miguel; Sánchez-Piedra, Carlos; Vispo, Eugenia; Barreiro, Pablo; McHutchison, John; Pineda, Juan Antonio; Soriano, Vincent // Clinical Infectious Diseases;11/15/2010, Vol. 51 Issue 10, p1209 

    Background. A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of...

  • Top topics in HCV research arena. Puoti, Massimo; Rossotti, Roberto; Travi, Giovanna; Orso, Maurizio; Cristina Moioli, Maria // BMC Infectious Diseases;2012, Vol. 12 Issue Suppl 2, p1 

    A significant improvement in the rate of eradication of Hepatitis C Virus Genotype 1 has been achieved with the addition of Boceprevir and Telaprevir to pegylated interferon and ribavirin. These two drugs are the heralds of a new wave of antivirals that will improve the efficacy of pegylated...

  • Hepatology.  // Current Medical Literature: Gastroenterology;2010, Vol. 29 Issue 3, p73 

    The article summarizes several studies related to hepatology. One study examines the significance of twelve weeks posttreament follow-up to identifying the sustained virologic response of hepatitis C patients to pegylated interferon and ribavirin. Another study investigates the effectiveness of...

  • Benefit--risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir. Gaetano, John N. // Drug, Healthcare & Patient Safety;2014, Vol. 6, p37 

    Greater understanding of the hepatitis C virus (HCV) genome and life cycle of the HCV virion allows for new targets for therapy that directly act on the viral machinery to inhibit replication. Numerous direct-acting antivirals are in development, and four have been brought to market. Simeprevir,...

  • Sustained Virologic Response to Peginterferon α-2a and Ribavirin in 335 Patients with Chronic Hepatitis C: A Tertiary Care Center Experience. Al Ashgar, Hamad; Khan, Mohammed Q.; Helmy, Ahmed; Al Swat, Khalid; Al Shehri, Abdullah; Al Kalbani, Abdalla; Peedikayel, Musthafa; Al Kahtani, Khalid; Al Quaiz, Mohammed; Rezeig, Mohammed; Kagevi, Ingvar; Al Fadda, Mohammed // Saudi Journal of Gastroenterology;Apr-Jun2008, Vol. 14 Issue 2, p58 

    Background/Aim: This retrospective study assessed the efficacy, safety, and the predictors of sustained viral response (SVR) to a 48-week-course of peginterferon α-2a (Pegasys) and ribavirin combination therapy in 335 consecutive Saudi patients with chronic hepatitis C virus (HCV) infection....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics